Sectors

RVTY
Revvity, Inc.
94.82
5 x 94.44
1 x 95.06
bid
ask
-
1.56
1.62%
10:13 AM
timesize
Ytd -1.99%
1y 4.89%
93.83
day range
95.25
82.26
52 week range
117.75
Open 94.45 Prev Close 96.38 Low 93.83 High 95.25 Mkt Cap 10.57B
Vol 121.42K Avg Vol 1.19M EPS 2.08 P/E 45.57 Forward P/E 16.36
Beta 1.05 Short Ratio 9.53 Inst. Own 103.66% Dividend 0.28 Div Yield 0.28
Ex Div Date 07-17 Earning 07-27 50-d Avg 90.06 200-d Avg 94.34 1yr Est 113.64
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 1.02 1.06 0.04 3.92%
2026-02-02 2025-12 1.63 1.7 0.07 4.29%
2025-10-27 2025-09 1.14 1.18 0.04 3.51%
2025-07-28 2025-06 1.14 1.18 0.04 3.51%
2025-04-28 2025-03 0.96 1.01 0.05 5.21%
2025-01-31 2024-12 1.36 1.42 0.06 4.41%
Upgrade / Downgrade
Date Firm Action From To
2026-05-07 Barclays Upgrade Equal-Weight Equal-Weight
2026-05-06 JP Morgan Upgrade Neutral Neutral
2026-05-06 TD Cowen Upgrade Buy Buy
2026-05-06 Stifel Upgrade Hold Hold
2026-05-04 Baird Upgrade Outperform Outperform
2026-04-14 Goldman Sachs Upgrade Neutral Neutral
Profile
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-05-06 BARRETT PETER Director 28.29K Stock Award(Grant)
2026-05-06 CHAPIN SAMUEL R. Director 22.68K Stock Award(Grant)
2026-02-04 GOLDBERG JOEL S General Counsel 106.96K Conversion of Exercise of derivative security
2026-02-03 KRAKOWIAK MAXWELL Chief Financial Officer 18.77K Stock Award(Grant)
2026-05-06 MICHAS ALEXANDROS P Director 71.54K Stock Award(Grant)
2025-08-26 MICHAS ALEXIS P Director 0.00 Sale
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. Rowe Price Investment Management, Inc. 22.45M 2.16B 20.12%
2025-12-30 Price (T.Rowe) Associates Inc 8.61M 829.68M 7.71%
2025-12-30 Edgepoint Investment Group Inc. 8.54M 822.84M 7.65%
2025-12-30 Janus Henderson Group PLC 8.16M 786.74M 7.32%
2026-03-30 Vanguard Capital Management LLC 7.33M 706.61M 6.57%
2026-03-30 Blackrock Inc. 7.25M 698.94M 6.50%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App 14.37M 1.38B 12.88%
2026-03-30 JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund 5.62M 542.21M 5.04%
2025-12-30 -Price (T.Rowe) U.S. Value Equity Trust 3.92M 378.28M 3.52%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 3.57M 344.05M 3.20%
2025-12-30 JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund 3.12M 301.18M 2.80%
2025-12-30 T. Rowe Price Value Fund, Inc. 3.03M 291.85M 2.71%
Dividend
Dividend Date
0.07 2026-07-17
0.07 2026-04-17
0.07 2026-01-16
0.07 2025-10-17
0.07 2025-07-18
0.07 2025-04-17